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Abstract
We have recently shown that a molecular biomarker signature comprised of inflammatory, hormonal and growth factors
occurs in the blood serum from first onset schizophrenia patients. Here, we use the same platform to investigate post
mortem brain tissue (Brodmann area 10) from schizophrenia patients who were mainly chronically ill and drug treated.
Twenty-one analytes are differentially expressed in post-mortem brain tissue. Comparison with our previous mRNA profiling
studies of the same patient samples in another frontal cortical area showed that 9 of these molecules were also altered at
the transcriptional level. Furthermore, 9 of the molecules were also altered in serum from living first onset schizophrenia
patients compared to controls. We propose a model in which the brain and periphery are coordinated through hormones
and other regulatory molecules released into the blood via the diffuse neuroendocrine system. These findings provide
further evidence for the systemic nature of schizophrenia and give added validity to the concept that schizophrenia can be
investigated through studies of blood-based biomarkers.
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Introduction
Schizophrenia is widely considered to be a heterogeneous
disorder with multiple causes. Diagnosis is made by means of
interview and despite some advances, no biological features with
clear diagnostic or prognostic power are known. This hinders
accurate diagnosis and thereby precludes the known benefits of
early treatment [1,2]. Although primarily considered a disorder of
the central nervous system, a peripheral component has been
demonstrated for schizophrenia [3,4,5,6,7]. However the relation-
ship between central and peripheral features is not understood.
Recently, we described the identification of a panel of blood-
based biomarkers which has high specificity and sensitivity in
distinguishing schizophrenia patients from controls, using a
multiplex immunoassay approach [3,8]. This panel consists of
proteins and small molecules related to metabolism, endocrine
function and inflammation, many of which have not been
described previously in schizophrenia. It is therefore of interest
to conduct a parallel investigation in brain tissue from schizo-
phrenia patients, to identify which, if any, of these markers are
differentially expressed in brain tissue. Furthermore, since
circulating factors such as hormones influence brain function, it
is of interest to identify which of these molecules link central and
peripheral function in schizophrenia.
Here, we use the same multiplex immunoassay platform to
investigate post mortem brain tissue from schizophrenia patients in
comparison to molecules identified in the serum of first onset
schizophrenia patients and those reported in the literature. The
aims of this study are to investigate the relationship between brain
and periphery in schizophrenia and the potential role of the serum
markers in schizophrenia symptomatology, and to add their
validity as diagnostic markers.
Materials and Methods
Biochemicals and reagents
All biochemicals and reagents were obtained from Sigma-
Aldrich (Poole, Dorsett, UK) unless stated otherwise.
Ethics statement
Brain tissue was obtained from the Stanley Medical Research
Institute. Tissue was collected post mortem from patients and
controls with full informed consent obtained from a first degree
relative after death in compliance with the Declaration of Helsinki.
In each case consent was obtained by questionnaires conducted
over the phone (since the next-of-kin were not on the premises of
the Medical Examiners Office at the time of autopsy) and signed
by two witnesses. The protocol was reviewed and accepted by the
Uniformed Services University of Health Sciences institutional
review board (IRB) and exemption from formal approval was
granted on the grounds that specimens were obtained via informed
donation from cadaveric material in accordance with federal and
state regulations, the research did not encompass genetic linkage
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studies, and all samples were de-identified and personal informa-
tion anonymised. Local ethical approval for use of this tissue was
granted by the Cambridgeshire 2 Local Research Ethics Com-
mittee.
Brain tissue
Fresh-frozen brain tissue blocks (Brodmann area 10) of
schizophrenia, bipolar disorder, and psychiatrically normal control
individuals were obtained from the Stanley Medical Research
Institute Array Collection (Table 1). Sample identities were coded,
blinded and randomised with respect to diagnosis to minimize
experimental or analytical bias. For continuous demographic
variables (age, pH, PMI) group differences between schizophrenia
and control samples were assessed by t-test. For gender, group
differences were assessed by Fisher’s exact test. Approximately
100 mg tissue from each block was minced into 10–20 ug
fragments on dry ice and combined with freshly prepared lysis
buffer [50 mM Tris- HCl (pH 7.4), containing Complete Mini
Protease Inhibitor Cocktail Tablets and Pepstatin (Roche Diag-
nostics Ltd, UK) in pre- chilled Lysing Matrix Tubes, type D (MP
Biomedicals; Cedex, France) at a ratio of 1 g tissue/9 mL buffer.
The tissues were homogenized twice for 20 seconds using a
FastPrepH-24 Instrument (MP Biomedicals) at a setting of 4.5 and
placed on ice for 30 seconds. The homogenates were transferred
to Eppendorf LoBind Protein tubes (Fisher Scientific Ltd;
Loughborough, UK) and centrifuged at 4uC for 3 minutes at
10,0006G in a refrigerated Heraeus Fresco17 Centrifuge (Fisher
Scientific Ltd). The supernatants were collected and stored at
280uC. Protein concentrations were determined using a DC
Protein Assay according to manufacturer’s instructions (Bio-Rad;
Hemel Hempstead, UK).
Multiplex immunoassay analysis
Extracts (200 mL) were analysed using the DiscoveryMAPTM
multiplexed immunoassay panel at Myriad-RBM (Austin, TX,
USA), comprising assays for 187 molecules (Table S1). Each assay
was calibrated using duplicate 8-point standard curves, and raw
intensity measurements were interpreted into final protein
concentrations using proprietary software. Machine performance
was verified using quality control samples at low, medium, and
high levels for each analyte.
Statistical analysis
Principal component analysis (PCA) (Umetrics AB; SIMCA-P+
12.0) was used to identify outliers. This showed that 3 samples lay
outside the confidence ellipse and were removed from further
analysis. Values which were outside the detection limits were
replaced with the minimum or maximum value for each assay as
appropriate. Assays showing less than 33% detectable values were
excluded from the analysis, leaving a total of 172 analytes available
for analysis. Further statistical analysis was carried out using SPSS
Statistics 17.0 (IBM). Correlation analysis was carried out to
investigate the effect of the demographic variables on the data.
Significant associations between the assay results, pH, PMI, age
and gender were identified and these variables were incorporated
into an ANCOVA model. The false discovery rate (FDR) was
controlled using the method of Benjamini and Hochberg [9].
Adjusted p values are denoted as q values throughout. Following
adjustment by ANCOVA, fold change was derived from the
estimated marginal mean of each group and expressed as mean/
control.
Haemoglobin immunoassay
A QuantichromTM Hemoglobin Assay Kit (BioAssay Systems;
Hayward, California, USA) was used to determine haemoglobin
levels in the supernatants as an indicator of the levels of blood
contamination in the brain samples. The assay was performed on
clear-bottom 96-well plates according to the manufacturer’s
recommendations. Briefly, 50 mL aliquots of each sample were
diluted at a ratio of 1:2 with 50 mM Tris-HCl buffer, combined
with 200 mL kit reagent and incubated for 5 minutes at room
temperature. Optical densities were determined at 400 nm using a
mQuantTM spectrophotometer (BioTek; Potton, UK). These
readings were converted to concentrations by comparison the
readings of a 5–75 mg/dL Hemoglobin Calibrator standard
curve. All samples were assayed in duplicate.
Uniplex immunoassays
Selected hits from the MAP analysis were replicated in-house
using individual enzyme-linked immunoadsorbent assays
(ELISAs). These were performed on a subset of samples chosen
according to their availability. At least 15 samples per group of
schizophrenia and control samples were extracted using the
method described above. ELISAs were performed for interferon
gamma (Abcam; Cambridge, UK), chromogranin A (ALPCO
Diagnostics; Salem, NH, USA) and tissue inhibitor of metallopro-
teinases-1 (TIMP-1) (Abnova; Tapei, Taiwan) according to the
manufacturers’ instructions.
Comparison with transcriptome data
MAP data was compared to microarray data derived from brain
tissue (BA9; [10]) and cerebral microvascular endothelial cells [11]
Table 1. Demographic details of brain tissue samples.
Control (n = 33) Schizophrenia (n =35)
Bipolar disorder
(n =33)
Gender (M/F) 25/8 26/9 15/18*
Age (years) 44.867.3 42.668.5 45.4610.8
Brain pH 6.6160.27 6.4760.24* 6.4460.30*
Post mortem interval (hours) 29.6613.2 31.4615.5 38.0618.9*
Lifetime antipsychotics (fluphenazine mg equivalent) 0 850046100335 9915623158
Duration of illness (years) na 21610.1 2069.6
In schizophrenia samples, no significant differences were observed in age (p = 0.241), gender (p = 0.990) or PMI (0.610), however there was a significant difference in
brain pH (p= 0.028). In bipolar disorder samples there were no significant difference in age (p = 0.801) but brain pH, PMI and gender differed significantly from control
(p = 0.015, 0.044 and p= 0.023 respectively).
doi:10.1371/journal.pone.0046368.t001
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from the same subjects. Full details of the microarray experiments
can be found in the relevant manuscripts. MAP analyte names
were converted to SwissProt identifiers and used to query the
Affymetrix database (NetAffx; www affymetrix.com). As cortisol
was one of the most significant analytes detected using the MAP
analyses, we also determined the expression level of mRNA
encoding the glucocorticoid receptor NR3C1. For correlation
analysis, raw MAP data were first log2 transformed for
comparability to the normalised microarray data. MAP data and
microarray transcriptomic data for the same subjects were then
tested using Pearson’s correlation within each diagnostic group.
Comparison with serum data
Data derived from brain tissue samples were compared to
those from our previously published analysis of serum samples
from 250 recent-onset schizophrenia patients, and 230 control
subjects [3] (Table 2). For this dataset [3], ethical committees
from the Universities of Cologne (cohort 1), Muenster (cohort 2)
and Magdeburg (cohorts 3 and 5) in Germany, and that from
Erasmus University (cohort 4) in the Netherlands, approved the
protocols of the study. Informed written consent was obtained for
all participants, diagnoses were carried out using the Diagnosis
and Statistical Manual (DSM)-IV and clinical tests performed by
psychiatrists. All patients selected for the study had the paranoid
subtype of schizophrenia (DSM-IV 295.30) with no other
medical conditions. Controls were recruited from geographical
areas matching the patient populations and those with no family
history of mental disease or other medical conditions were
selected for the study. Briefly, non-parametric, two-tailed
Wilcoxon rank-sum tests were carried out to identify significant
expression differences between patients and controls as described
in Schwarz et al [3]. For the purposes of comparison with the
brain dataset, we wished to use the most reproducible set of
markers, therefore we only considered molecules which were
replicated in at least 2 cohorts.
Targeted analyte clustering
A targeted analyte cluster (TAC) approach was applied to
identify molecules which show correlated expression levels in the
datasets, as described previously (Cheng et al, 2010). In this
method, correlated analytes are identified by analyzing the data in
reproducing kernel spaces. Analytes were pre-classified into broad
categories of ‘‘metabolic’’, ‘‘immune’’ and ‘‘other’’ analytes, based
on functional annotation database searching in order to reduce the
datasets to a manageable size as well as to increase the likelihood
of identifying biologically relevant clusters. The analysis was then
performed within these categories, plus ‘‘metabolic’’ and ‘‘im-
mune’’ analytes together and all analytes together. TAC examined
small analyte clusters within each category and ranked their
precision (true positive predictions divided by the sum of true
positive and false positive predictions) in terms of distinguishing
schizophrenia from control subjects in brain tissue. We then tested
the top clusters in the serum data (cohort 1 only), in order to
identify clusters which had similar discriminatory power in serum
as in brain. The analysis was then performed in reverse, by
identifying correlated analyte clusters in the serum data which
were then tested on the brain dataset to determine if these could
separate schizophrenia and control subjects. To further identify
clusters that specifically give a good prediction power in
distinguishing schizophrenia from controls but not bipolar
disorder from controls, we also tested the ability of those
schizophrenia-associated clusters to separate bipolar disorder
patients from controls. In addition, interactions between members
of a cluster were investigated in silico using the Ingenuity Pathways
Knowledgebase (www.ingenuity.com).
Results
Multiplex immunoassay analyses of brain tissue
Analysis of schizophrenia and control brain tissue using
multiplexed immunoassay profiling identified 21 analytes which
showed significant differences (p,0.05) after adjusting for
covariates using ANCOVA (see Table S2 for details of the
Table 2. Demographic details for the serum cohorts [3].
Cohort no: SCZ1 SCZ2 SCZ3 SCZ4 SCZ5 BPD1
Patients n 71 46 46 47 40 32
Controls n 59 46 45 40 40 59
Patients (M/F) 42/29 35/11 30/16 36/11 27/12 13/19
Controls (M/F) 31/28 35/11 27/18 33/7 26/14 31/28
Patients Age 31610 2769 35612 2668 35610 34610
Controls Age 3068 2769 34612 2764 36611 3068
Patients BMI 2465 2262 2665 na 2565 2564
Controls BMI 2364 na 2464 na 2463 2364
Patients Smoking (Y/N/na) 25/23/23 16/26/4 25/21/0 33/14/0 22/18/0 7/14/11
Controls Smoking (Y/N/na) 25/34/0 na 11/34/0 na 18/22/0 25/34/0
Patients Cannabis (Y/N/na) 33/22/16 15/27/4 8/38/0 23/24/0 7/33/0 7/14/11
Controls Cannabis (Y/N/na) 31/25/3 na 0/45/0 na 3/37/0 31/25/3
Medication free patients all all 33 all all 4
PANSS positive item score 2366 1867 2165 na 2367 na
PANSS negative item score 2368 1867 2267 na 1968 na
Schizophrenia subjects are first or recent-onset as described in [3]. The same controls are used for SCZ1 and BPD1. Values are shown as mean6s.d. Abbreviations: BMI,
body mass index; M/F, male/female; na, not available; PANSS, positive and negative syndrome scale; SCZ, schizophrenia; Y/N, yes/no.
doi:10.1371/journal.pone.0046368.t002
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covariate analysis). The false discovery rate-adjusted q values
ranged between 0.17 and 0.4. A potential confounding factor in
this analysis lies in the range of analytes tested, which primarily
target circulating factors. As the brain tissue was dissected post
mortem, samples contain blood as well as tissue. It is expected that
in the majority of cases any contaminating blood will have been
washed out and the ratio of blood to tissue will be extremely small,
meaning that measured analyte expression levels will be derived
principally from the tissue. However if a high degree of variability
exists in the amount of blood contamination between samples, an
artefactual difference in analyte levels between samples may be
detected. We used a haemoglobin assay as a proxy measure for the
amount of blood contamination in each tissue sample. Samples
contained 34.0+/217.5 mg/dl Hb with no significant difference
between schizophrenia and control samples (p = 0.43). However, 5
analytes showed significant correlations with haemoglobin levels.
Incorporation of Hb levels into the ANCOVA model showed that
only 3 of 21 analytes were no longer significant and 2 new analytes
became significant. False discovery rate-adjusted q values ranged
between 0.28 and 0.45 (Table 3). The largest fold changes were
seen for C-reactive protein (8.3-fold), interferon-c (2.5-fold),
fibroblast growth factor-4 (22.5-fold), macrophage inflammatory
protein-1b (22.8-fold) and glutathione S-transferase [23.3-fold;
which reached significance only after ANCOVA adjustment for
Hb level (p = 0.0.050)]. These findings suggested alterations in
inflammatory pathways in the brain which were not explained by
differing levels of blood contamination.
Samples from bipolar disorder patients were also analysed. Five
analytes were significantly altered in bipolar disorder, however the
false discovery rate was high in all cases (four out of five analytes
had q values.0.9), both with and without the inclusion of Hb as a
covariate (data not shown). This suggests that there is no strong
biomarker profile for bipolar disorder in this tissue, considering the
analytes targeted by the platform and given the differences in
demographic variables between patients and controls. Similar
results were obtained for bipolar disorder in frontal cortex of the
same brain series by whole genome microarray [12].
Validation
ELISA. The results of three of the differentially expressed
brain proteins were validated using uniplex ELISA tests in
schizophrenia and control samples. This confirmed that interfer-
on-c (p=0.043, FC=1.4) and chromogranin A (p=0.004,
FC=21.3) were present at significantly different levels between
schizophrenia and control samples (Figure 1). The same analysis
showed that TIMP-1 had a fold change consistent with the
multiplex immunoassay data, although this did not reach
significance (p = 0.15, FC=1.3). However, the uniplex ELISA
and multiplex immunoassay results were significantly correlated
for this analyte (r = 0.87; p,0.0001).
mRNA levels. We have previously analyzed prefrontal cortex
tissue from the same individuals at the mRNA transcript level
using whole genome microarrays on both brain tissue homogenate
and laser microdissected microvascular endothelium. As some of
the analytes are expected to be localised to endothelium, we
investigated mRNA levels from both datasets. In the case of the
steroid hormone cortisol, transcripts for the glucocorticoid
receptor (NR3C) were investigated. This showed that 9 molecules
(NR3C receptor, TIMP1, VCAM1,, prostatic acid phosphatise,
cancer antigen 125, chromogranin A, thrombopoeitin, immuno-
globulin E, and MIP-1b) were significantly altered at both the
protein and transcript levels, although fold changes were not
generally in agreement (Table 3). Similar disagreements in
direction of fold change between mRNA and the corresponding
protein levels have been reported previously [13]. Interestingly,
cortisol levels determined by multiplex immunoassay analysis were
found to be negatively correlated with levels of the glucocorticoid
receptor transcript (NR3C) in brain tissue homogenate from
patients but not controls (r=20.41; p=0.017). This is consistent
with downregulation of the glucocorticoid receptor by chronic
hypercortisolemia. Conversely the glucocorticoid receptor appears
to be upregulated in microvascular endothelium, providing further
evidence for abnormalities in the cortisol pathway. This pathway
has tissue-specific functions in the blood brain barrier, where
glucocorticoid receptors are responsible for the closing of tight
junctions [14].
Univariate comparison of brain and serum analyte levels
The same molecules which were identified as significantly
altered in post mortem brain tissues from schizophrenia patients were
also analyzed in serum from living first onset schizophrenia
(n = 250) and control (n = 230) subjects over 5 cohorts, using the
same multiplex immunoassay platform. P-values were calculated
in each cohort using two-tailed Wilcoxon rank-sum tests. This
showed that 9 of the analytes (C-reactive protein, cortisol, resistin,
TIMP-1, chromogranin A, VEGF, thrombopoetin, alpha-2
Figure 1. Enzyme-linked immunoadsorbent assay validation of changes in brain protein levels. A subset of the same brain samples used
for multiplex immunoassay analysis was analyzed using uniplex ELISAs as indicated. All 3 proteins tested showed consistent results with the findings
in the multiplex immunoassay analysis. Interferon-c, p= 0.043, FC= 1.4; Chromogranin A, p= 0.004, FC =21.3; tissue inhibitor of metalloproteinases 1
(TIMP-1), p=0.15, FC 1.3. FC= fold change.
doi:10.1371/journal.pone.0046368.g001
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macroglobulin, and glutathione S-transferase) were also found to
be reproducibly altered between schizophrenia and control
subjects in serum (Table 3). In addition, 4 of these analytes
showed opposite changes in brain and serum, which may indicate
counter-regulation of these proteins between the brain and
periphery.
Multivariate comparison of brain and serum analyte
levels
We used a targeted analyte cluster (TAC) approach to identify
molecules which are correlated at the multivariate level in the
brain dataset. This method identifies clusters of analytes which
have the strongest influence on the data without necessarily
requiring significance at the univariate level. These correlations
are likely for molecules which are co-regulated as components of
similar or identical molecular pathways. We investigated the brain
data for clusters of analytes that could be used to distinguish
schizophrenia from normal control subjects and then looked for
those which gave high precision in both brain and serum, after
correction for demographic variables. To further identify clusters
that specifically give a good prediction power in distinguishing
schizophrenia from controls but not bipolar disorder from
controls, we also tested the ability of those schizophrenia-
associated clusters to separate bipolar disorder patients from
controls. As a result, thirteen clusters were identified in the brain
dataset that distinguished between patients and controls with
significantly higher precision in predicting schizophrenia than
bipolar disorder; however, only four of these were also detectable
in serum (Table S3a, Figure S1). A cluster consisting of alpha-2-
macroglobulin, plasminogen activator inhibitor 1, prostatic acid
phosphatase and serum glutamic oxaloacetic transaminase could
distinguish schizophrenia from controls in both brain tissue and
serum with a good precision (69% and 70%,respectively), but has a
consistently low precision value in the case of distinguishing
bipolar disorder from normal controls (,50% precision in both
brain tissue and serum)(Figure 2A; Table S3b). An Ingenuity
Pathway Analysis network indicates that these 4 molecules interact
via IL1b, which shows a trend for differential expression in brain
(p = 0.09) but not serum, and has previously been shown to be
altered in schizophrenia CSF [15] and serum [16](Figure 2C).
Therefore this cluster may provide an example of how altered
brain biochemistry is reflected in serum analytical profile
specifically for schizophrenia, and provides a useful starting point
for further study. We performed the converse analysis by
identifying clusters of analytes in serum which also gave high
precision in brain tissue. 11 clusters were identified in the serum
data that distinguished between patients and controls with
significantly higher precision in schizophrenia than bipolar
disorder (Table S4a, Figure S2). The cluster giving the best
performance in both serum and brain tissue consisted of alpha-2
macroglobulin, cortisol, alpha-1 antitrypsin, sex hormone binding
globulin and sortilin (Figure 2B, Table S4b).
Discussion
Recent studies have shown that biomarkers for schizophrenia
can be reliably detected in the bloodstream [3,8]. However the
relationship of these biomarkers to schizophrenia neuropathology
is unclear. Here, we have shown that a subset of these analytes
which are predominantly involved in the inflammatory response
are differentially expressed in post mortem brain tissue from
schizophrenia patients, and similar patterns of change can be
observed in schizophrenia brain tissue as in the periphery. This
provides further evidence for the systemic nature of schizophrenia
and provides additional validity to the previously published
peripheral biomarkers. However, there are a number of limitations
of the study. Firstly the difference in brain regions (BA9/10)
between microarray and multiplex immunoassay data limits the
potential to observe comparable findings between the datasets.
Secondly, the difference in patient selection between post mortem
brain samples, generally obtained from patients who were drug
treated either at time of death or during their life, and after several
years of illness, and serum samples from living patients who were
drug naive and suffering their first episode of schizophrenia,
complicates comparison between sample sets. We have previously
Figure 2. Brain vs serum analysis. Targeted analyte cluster analysis was performed to identify clusters of co-behaving analytes having the ability
to distinguish schizophrenia from control with significantly greater precision than bipolar disorder from control. The cluster derived from brain tissue
data showing the most similarity in serum data consisted of alpha-2 macroglobulin + plasminogen activator inhibitor-1 + prostatic acid phosphatase
+ serum glutamic oxaloacetic transaminase (A). The cluster derived from serum data showing the most similarity in brain data consisted of alpha-1
antitrypsin, alpha-2 macroglobulin + cortisol + sex hormone binding globulin + sortilin (B). (C) Ingenuity Pathways Analysis was performed on the
cluster of co-behaving analytes derived from brain tissue (schizophrenia vs control) which gave most similar results in serum. The analysis shows that
these four molecules (marked in green) interact via IL1b (marked in orange), which has previously been found altered in schizophrenia (see text for
details). Solid lines represent physical interactions (i.e. binding), whereas arrows represent any other type of indirect cellular interactions. PAI-1
plasminogen activator inhibitor-1, GOT1 serum glutamic oxaloacetic transaminase, A2M alpha-1 macroglobulin, PAP prostatic acid phosphatase.
Other members of network represented by HUGO gene symbols.
doi:10.1371/journal.pone.0046368.g002
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shown the serum biomarkers are robust before and after treatment
and in chronic illness [8]. Nonetheless, a small number of analytes
are correlated with either lifetime antipsychotic treatment or
duration of illness as shown in Table S2, therefore these data
should be interpreted with caution. Future studies should be
carried out which link peripheral blood, brain imaging and post
mortem studies within the same patients.
The co-ordination between the brain and periphery is likely to
be mediated through the circulatory system which contains a
number of secreted regulatory molecules and hormones which
target multiple systems of the body, including the central nervous
system. Hormones are produced in the diffuse neuroendocrine
system which includes the hypothalamus, pituitary, adrenals,
pancreatic islet cells, gonads, gut and adipose tissue. Previously, we
have shown that the level of a number of hormones are altered in
post mortem pituitary glands from schizophrenia patients com-
pared to control subjects [17]. These included increased levels of
pro-opiomelanocortin peptides and decreased levels of growth
hormone, prolactin and arginine vasopressin. All of these
molecules have been shown to have effects on various aspects of
central nervous system function including inflammation [18], sleep
[19], regulation of dopamine levels [20] and neurotrophic effects
[21]. We have also demonstrated that the levels of hormones such
as insulin, cortisol, progestone, prolactin, growth hormone and
chromogranin A are altered in the circulation of first onset
schizophrenia patients compared to controls [4].
Notably, insulin has been shown to cross the blood brain barrier
and has a number of effects on central nervous system functions
including alterations in ligand-gated ion channel trafficking and
modulation of the tone of synaptic transmission by regulation of
cell-surface expression of inhibitory and excitatory receptors [22].
Other studies have shown that insulin can have direct effects on
synaptic plasticity and cognitive function [23]. In addition,
emerging evidence suggests that central administration of insulin
may enhance cognitive function in diseased and healthy individ-
uals [24]. For example, insulin and insulin-like growth factor-1, or
insulin-sensitizing agents), may offer novel disease-modifying
neurocognitive treatments or protect against neurodegeration
[25].
Although the multiplex immunoassay panel primarily targets
blood analytes, the majority of the significant molecules identified
here are known to be expressed in vascularised brain tissue.
Furthermore, several of the significant analytes have been
reported to be altered in previous studies of schizophrenia
patients, although most of these changes have been identified in
the periphery. C-reactive protein has been found at increased
levels in serum from schizophrenia patients and this was
associated with the severity of cognitive impairment [3,8,26,27].
This protein is expressed in a variety of cell types including
neurons [28]. Altered secretion of interferon-gamma from
PBMCs has been reported in schizophrenia [29,30], albeit with
conflicting results, although altered brain expression has not
previously been described. Immunoglobulin E has previously
been shown to be increased in serum of treatment-resistant
schizophrenia patients [31]; we found decreased levels of this
protein in brain tissue. Immunoglobulin E receptors are
expressed on peripheral neurons [32] but brain expression is
unclear, despite the fact that other immunoglobulin subtypes are
expressed in the brain [33]. There is some evidence for altered
expression of plasminogen activator inhibitor-1 in drug-treated
schizophrenia patients [34]. Decreased levels of vascular endo-
thelial growth factor have previously been reported in the
dorsolateral prefrontal cortex of schizophrenia patients [35],
consistent with the findings of our study. A further link with
published data on schizophrenia is provided by prostatic acid
phosphatase, seen to be increased here, which dephosphorylates
Erbb2, a receptor for the schizophrenia susceptibility gene
product neuregulin [36].
For some of the analytes that we have identified here, there is no
reported expression in neuronal, glial or vascular cell types (cancer
antigen 19-9, cancer antigen 125, MIP1-beta, cortisol). This
suggests that the presence of such analytes in the brain could be
due to blood contamination. However, we have excluded the
possibility that the differences in the levels of these molecules were
due to inter-sample variability in blood contamination. In the case
of cortisol, its presence in the brain may be through binding or
internalization in target tissues. The finding of increased levels of
cortisol in schizophrenia patients is well-documented. However,
the function and/or location of other molecules in the brain is not
clear (cancer antigen 19-9, cancer antigen 125, MIP1-beta) and
further work is required in these cases.
The finding of alterations in the levels of several endothelial-
related markers is of interest and adds to previous evidence for
abnormal blood-brain barrier function in schizophrenia [11]. For
example, we found increased levels of adiponectin in the brain and
this protein is known to accumulate in damaged blood vessels.
Furthermore the matrix metalloproteinase 1/tissue inhibitor of
metalloproteinase 1 (MMP1/TIMP1) pathway may contribute to
the breakdown of the blood brain barrier in conditions such as
Alzheimer’s disease [37] and diabetes [38]. Our finding of
increased TIMP1 and decreased MMP1 is consistent with
previous reports and suggests a cytoprotective role of this pathway
in the brains of schizophrenia patients. The proteins vascular cell
adhesion molecule (VCAM1) and vascular endothelial growth
factor (VEGF) showed opposite directions of change in brain and
serum. VEGF has previously been reported to be decreased in
schizophrenia brain [35], consistent with the present findings.
Circulating levels of this molecule are increased following
hypoglycaemia and this effect is associated with preserved
cognitive function under hypoglycaemic conditions [39]. Thus
the dysregulation of VEGF seen here may reflect an attempt to
counteract abnormal glucose handling in the schizophrenia brain.
VCAM1 is expressed on cytokine-activated endothelium. There-
fore, the altered levels of this protein found in this study are
consistent with an abnormal inflammatory status in the cerebral
microvasculature of schizophrenia patients [11]. The function of
the circulating form is unclear but is thought to be associated with
microvascular dysfunction [40] and/or atherosclerotic damage
[41].
Conclusions
Here we found changes in analytes in post mortem brains of
schizophrenia patients which appear to be linked to changes in the
same molecules in circulation of living schizophrenia patients. We
propose a model in which the central nervous system and
periphery are linked via components of the diffuse neuroendocrine
system, such as cortisol, insulin, leptin, pro-opiomelanocortin,
prolactin and growth hormone. However, it should be noted that
to fully investigate the systemic nature of schizophrenia, prospec-
tive studies must be carried out which link peripheral blood, brain
imaging and post mortem studies within the same patients. Further
studies in this area are important to increase our understanding of
the pathophysiological pathways underlying schizophrenia and
other psychiatric disorders which, in turn, could lead to novel
beneficial strategies for therapeutic intervention.
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